Strattera (Atomoxetine) Sexual Side Effects
Strattera (atomoxetine) can impair sexual function, including changes in sexual desire, sexual performance, and sexual satisfaction. [1] In clinical trials, sexual adverse reactions were assessed in adults and were reported as erectile dysfunction and ejaculation disorder, with additional libido changes documented in labeling. [1] Sexual dysfunction should be routinely inquired about because trial estimates may underestimate incidence. [1, 2]
Erectile Dysfunction and Ejaculatory Disorders
Erectile dysfunction is a labeled sexual adverse reaction associated with atomoxetine. [1] Ejaculation disorder is a labeled sexual adverse reaction associated with atomoxetine. [1] In pooled analysis of atomoxetine treatment-emergent adverse events, onset of the more common genitourinary treatment-emergent adverse events occurred relatively early in dosing in adult males. [3]
Decreased Libido and Other Sexual-Function Changes
Libido changes (including decreased libido) are reported in atomoxetine labeling under sexual side effects. [1] The assessment of changes in sexual desire, sexual performance, and sexual satisfaction is limited in most clinical trials, which supports routine clinical inquiry. [1]
Priapism and Urinary-Genital Red Flags
Priapism has been reported postmarketing for pediatric and adult patients treated with atomoxetine. [1] Priapism is defined as painful and nonpainful penile erection lasting more than 4 hours. [1] Priapism requires prompt medical attention, including immediate medical evaluation because of potential lasting damage. [1] Urinary hesitancy and urinary retention are labeled urogenital adverse events, which may co-occur with sexual dysfunction symptoms. [1]
Evaluation Framework for Sexual Adverse Effects
Sexual adverse effects should be identified through routine patient inquiry for erectile and ejaculatory dysfunction while taking atomoxetine. [2] Assessment should determine temporal association between symptom onset and atomoxetine dosing changes because treatment-emergent genitourinary events show early onset patterns in adult males in pooled trial data. [3] Evaluation should distinguish atomoxetine-associated symptoms from other contributors such as baseline sexual dysfunction, comorbid depression/anxiety, substance use, and medication changes that affect sexual function. [1] For any symptoms consistent with priapism, immediate in-person medical evaluation is indicated without delay. [1]
Management Strategy for Mild-to-Moderate Sexual Dysfunction
Atomoxetine-associated sexual adverse effects should prompt discussion of symptom burden and ongoing sexual functioning. [1, 2] Medication strategy should incorporate dose adjustment or discontinuation consideration when sexual adverse effects are bothersome or do not resolve. [1] Switching to an alternative ADHD medication is supported for management when adverse effects outweigh benefit, consistent with structured ADHD adverse-effect management approaches that include monitoring for sexual dysfunction with atomoxetine. [2]
Discontinuation or Urgent Care Indications
Immediate medical attention is required for priapism lasting more than 4 hours during atomoxetine treatment. [1] Urgent evaluation is indicated for severe, abrupt-onset, or persistent adverse reactions when they are not part of the presenting symptom profile. [1]
Monitoring Plan While Continuing Atomoxetine
Ongoing monitoring should include evaluation for sexual dysfunction in young people and adults receiving atomoxetine, with attention to erectile and ejaculatory dysfunction. [2] Routine inquiry should continue because estimates from clinical trials may underestimate the true incidence of sexual dysfunction experiences. [1]
Key Evidence Supporting These Associations
Atomoxetine labeling reports that clinicians should routinely inquire about possible sexual side effects because clinical trial assessments of sexual satisfaction and performance are limited. [1] Pooled analysis of clinical-trial treatment-emergent adverse events found that genitourinary treatment-emergent adverse events in adult males tended to occur relatively early after dosing initiation. [3] Atomoxetine labeling also documents labeled frequencies for erectile dysfunction and ejaculation disorder in adult CYP2D6 poor metabolizers and notes sexual impairment in some patients. [1]
Sexual Dysfunction Differential Diagnosis Considerations
Differential diagnosis should include medication-related causes beyond atomoxetine, because changes in sexual desire and sexual satisfaction are not well captured in most trials and because multiple concurrent factors may contribute. [1] Assessment should screen for contributing urogenital symptoms such as urinary hesitation or urinary retention when sexual symptoms occur, since these are labeled with atomoxetine. [1]